NEW YORK – Natera on Tuesday sued molecular diagnostics and consulting firm Genosity for alleged patent infringement relating to technology from ArcherDx.
In its complaint, filed with the US District Court for the District of Delaware, Natera claimed that several of Genosity's products infringe its US Patent No. 10,732,220, titled "Methods for Simultaneous Amplification of Target Loci."
The products, which include Genosity's AsTra testing system, AsTra Profile, AsTra One, AsTra Next, and Myeloid NGS Molecular Profile, all use ArcherDx's circulating tumor DNA chemistry and primers, according to Natera.
In August, Natera had separately filed suit against ArcherDx – now part of Invitae – alleging infringement of the same patent. That action was consolidated last month with a suit Natera had filed against ArcherDx earlier this year.
In its latest complaint, Natera claimed that Genosity, based in Iselin, New Jersey, does not have freedom to operate its AsTra products for minimal residual disease and personalized cancer monitoring.
Natera asked for a jury trial, judgment that Genosity infringes the '220 patent, an injunction to prevent Genosity from further infringement, and damages and trial costs.
A Natera spokesperson said the company has no comment on the lawsuit at this time.